Replies to post #188 on Evolus (EOLS)

[DewDiligence]

EOLS 2Q22 product_sales=$37.2M—6/30/22_cash=$84.5M—(down from $106.7M @3/31/22):

https://investors.evolus.com/press-releases-and-news/news-details/2022/Evolus-Reports-Second-Quarter-2022-Results-and-Provides-Business-Update/default.aspx

2Q22 Jeuveau sales of $37.2 were +12% QoQ, consistent with seasonal trends in the aesthetics business.

EOLS reiterated guidance for 2022 Jeuveau sales to be at the high end of the $143-150M range, but this won’t be enough to reach breakeven operations.

EOLS continues to expect the EU launch of Jeuveau/Nuceiva in 3Q22.